Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19182356 | 0.88 | HTR1A (0.35) | PTGS2HTR1AHTR7PSMB5HTR6 | |
| SCHEMBL29732972 | 0.87 | PTGS2 (0.40) | CAMKK2PTGS2HTR1AHTR7PSMB5 | |
| SCHEMBL2969965 | 0.86 | PTGS2 (0.40) | CAMKK2PTGS2HTR1AHTR7PSMB5 | |
| SCHEMBL287733 | 0.82 | S1PR1 (0.38) | PTGS2HTR1AHTR7PSMB5PTPRC | |
| SCHEMBL28747404 | 0.81 | HTR1A (0.37) | HTR1AHTR7PSMB5HTR6 | |
| SCHEMBL28278174 | 0.79 | ADRA2A (0.35) | CAMKK2PTGS2HTR1AADRA2AADRA2B | |
| SCHEMBL28000625 | 0.79 | ABCB1 (0.42) | PTGS2HTR1AHTR7 | |
| SCHEMBL641745 | 0.79 | PTPN5 (0.37) | CAMKK2PTGS2HTR6NSD2ALDH1A1 | |
| SCHEMBL5379529 | 0.78 | PTPN1 (0.35) | PTGS2ALDH1A1LMNAL3MBTL1ADRA2A | |
| SCHEMBL28855915 | 0.78 | HTR1A (0.42) | PTGS2HTR1AHTR7PSMB5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190854-A1 | Hydroamination of Alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-07-26 | — | — | US | claimed |
| US-8188302-B2 | Hydroamination of alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-05-29 | — | — | US | claimed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | claimed |
| US-20230203077-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | NATIONAL SCIENCE FOUNDATION | 2023-06-29 | — | — | US | disclosed |
| US-11603381-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2023-03-14 | — | — | US | disclosed |
| US-11384075-B2 | Quinolinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210139470-A1 | New Quinolinone Compounds | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| US-20210061834-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | NATIONAL SCIENCE FOUNDATION | 2021-03-04 | — | — | US | disclosed |
| US-10894802-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2021-01-19 | — | — | US | disclosed |
| US-20030195188-A1 | Pyridine and quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-16 | — | — | US | disclosed |
| EP-1210320-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202959-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1-BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| EP-1194426-A2 | BENZOFURANE DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001005749-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001004112-A2 | BENZOFURANE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156824-A1 | Hydroamination of Alkenes | HRH3, HRH4, H1-3 | CAMKK2 3398/4885PTGS2 3835/4885HTR1A 1358/4885 |
| US-11603381-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | CAMKK2 2683/4885PTGS2 293/4885HTR1A 4671/4885 |
| US-20210061834-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | CAMKK2 2871/4885PTGS2 231/4885HTR1A 4651/4885 |
| US-20230203077-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | CAMKK2 2871/4885PTGS2 231/4885HTR1A 4651/4885 |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | CAMKK2 1613/4885PTGS2 1130/4885HTR1A 987/4885 |
| US-20210139470-A1 | New Quinolinone Compounds | FGFR1, FGFR2, FGFR3 | CAMKK2 2096/4885PTGS2 2107/4885HTR1A 3110/4885 |
| US-20030195188-A1 | Pyridine and quinoline derivatives | DPP4, DPP3, DPP7 | CAMKK2 3162/4885PTGS2 2345/4885HTR1A 410/4885 |
| US-10894802-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | CAMKK2 2683/4885PTGS2 293/4885HTR1A 4671/4885 |
| US-11384075-B2 | Quinolinone compounds | FGFR1, FGFR2, FGFR3 | CAMKK2 2457/4885PTGS2 2137/4885HTR1A 3279/4885 |
| US-20120190854-A1 | Hydroamination of Alkenes | HRH3, HRH4, H1-3 | CAMKK2 3398/4885PTGS2 3835/4885HTR1A 1358/4885 |
| US-11332435-B2 | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient | FABP3, PCCA, HMGCR | CAMKK2 1613/4885PTGS2 1130/4885HTR1A 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.